Asthma and COPD Drugs Market (By Diseases: Asthma, COPD; By Medication Class: Combination Drugs, Bronchodilators, Inhaled Corticosteroids (ICS), Short Acting Beta Agonists (SABA), Long Acting Beta Agonists (LABA), Leukotriene Antagonists (LTA), Anticholinergics, Anti-Inflammatories, Others; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022 – 2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Asthma and COPD Drugs Market 

5.1. COVID-19 Landscape: Asthma and COPD Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Asthma and COPD Drugs Market, By Diseases

8.1. Asthma and COPD Drugs Market, by Diseases Type, 2022-2030

8.1.1. Asthma

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. COPD

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Asthma and COPD Drugs Market, By Medication Class

9.1. Asthma and COPD Drugs Market, by Medication Class, 2022-2030

9.1.1. Combination Drugs

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Bronchodilators

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Inhaled Corticosteroids (ICS)

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Short Acting Beta Agonists (SABA)

9.1.4.1. Market Revenue and Forecast (2017-2030)

9.1.5. Long Acting Beta Agonists (LABA)

9.1.5.1. Market Revenue and Forecast (2017-2030)

9.1.6. Leukotriene Antagonists (LTA)

9.1.6.1. Market Revenue and Forecast (2017-2030)

9.1.7. Anticholinergics

9.1.7.1. Market Revenue and Forecast (2017-2030)

9.1.8. Others

9.1.8.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Asthma and COPD Drugs Market, By Distribution Channel 

10.1. Asthma and COPD Drugs Market, by Distribution Channel, 2022-2030

10.1.1. Hospital Pharmacies

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Retail Pharmacies

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Online Pharmacies

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Drug Stores

10.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Asthma and COPD Drugs Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Diseases (2017-2030)

11.1.2. Market Revenue and Forecast, by Medication Class (2017-2030)

11.1.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Diseases (2017-2030)

11.1.4.2. Market Revenue and Forecast, by Medication Class (2017-2030)

11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Diseases (2017-2030)

11.1.5.2. Market Revenue and Forecast, by Medication Class (2017-2030)

11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Diseases (2017-2030)

11.2.2. Market Revenue and Forecast, by Medication Class (2017-2030)

11.2.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Diseases (2017-2030)

11.2.4.2. Market Revenue and Forecast, by Medication Class (2017-2030)

11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Diseases (2017-2030)

11.2.5.2. Market Revenue and Forecast, by Medication Class (2017-2030)

11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Diseases (2017-2030)

11.2.6.2. Market Revenue and Forecast, by Medication Class (2017-2030)

11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Diseases (2017-2030)

11.2.7.2. Market Revenue and Forecast, by Medication Class (2017-2030)

11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Diseases (2017-2030)

11.3.2. Market Revenue and Forecast, by Medication Class (2017-2030)

11.3.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Diseases (2017-2030)

11.3.4.2. Market Revenue and Forecast, by Medication Class (2017-2030)

11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Diseases (2017-2030)

11.3.5.2. Market Revenue and Forecast, by Medication Class (2017-2030)

11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Diseases (2017-2030)

11.3.6.2. Market Revenue and Forecast, by Medication Class (2017-2030)

11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Diseases (2017-2030)

11.3.7.2. Market Revenue and Forecast, by Medication Class (2017-2030)

11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Diseases (2017-2030)

11.4.2. Market Revenue and Forecast, by Medication Class (2017-2030)

11.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Diseases (2017-2030)

11.4.4.2. Market Revenue and Forecast, by Medication Class (2017-2030)

11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Diseases (2017-2030)

11.4.5.2. Market Revenue and Forecast, by Medication Class (2017-2030)

11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Diseases (2017-2030)

11.4.6.2. Market Revenue and Forecast, by Medication Class (2017-2030)

11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Diseases (2017-2030)

11.4.7.2. Market Revenue and Forecast, by Medication Class (2017-2030)

11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Diseases (2017-2030)

11.5.2. Market Revenue and Forecast, by Medication Class (2017-2030)

11.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Diseases (2017-2030)

11.5.4.2. Market Revenue and Forecast, by Medication Class (2017-2030)

11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Diseases (2017-2030)

11.5.5.2. Market Revenue and Forecast, by Medication Class (2017-2030)

11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

Chapter 12. Company Profiles

12.1. Pfizer Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Teva Pharmaceutical Industries Ltd

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Merck & Co. Inc

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Grifols S.A.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Novartis AG

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Cipla Inc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Abbott

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Astellas Pharma

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Hoffmann-La Roche Ltd

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Glenmark Pharmaceuticals

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

PROCEED TO BUY

   USD 4500
   USD 7000
   USD 9000

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample